Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer

Fibrocytes are hematopoietic stem cell–derived fibroblast precursors that are implicated in chronic inflammation, fibrosis, and wound healing. Myeloid-derived suppressor cells (MDSCs) expand in cancer-bearing hosts and contribute to tumor immune evasion. They are typically described as CD11b+HLA-DR–...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 122; no. 7; pp. 1105 - 1113
Main Authors Zhang, Hua, Maric, Irena, DiPrima, Michael J., Khan, Javed, Orentas, Rimas J., Kaplan, Rosandra N., Mackall, Crystal L.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 15.08.2013
American Society of Hematology
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Fibrocytes are hematopoietic stem cell–derived fibroblast precursors that are implicated in chronic inflammation, fibrosis, and wound healing. Myeloid-derived suppressor cells (MDSCs) expand in cancer-bearing hosts and contribute to tumor immune evasion. They are typically described as CD11b+HLA-DR– in humans. We report abnormal expansions of CD11b+HLA-DR+ myeloid cells in peripheral blood mononuclear fractions of subjects with metastatic pediatric sarcomas. Like classical fibrocytes, they display cell surface α smooth muscle actin, collagen I/V, and mediate angiogenesis. However, classical fibrocytes serve as antigen presenters and augment immune reactivity, whereas fibrocytes from cancer subjects suppressed anti–CD3-mediated T-cell proliferation, primarily via indoleamine oxidase (IDO). The degree of fibrocyte expansion observed in individual subjects directly correlated with the frequency of circulating GATA3+CD4+ cells (R = 0.80) and monocytes from healthy donors cultured with IL-4 differentiated into fibrocytes with the same phenotypic profile and immunosuppressive properties as those observed in patients with cancer. We thus describe a novel subset of cancer-induced myeloid-derived suppressor cells, which bear the phenotypic and functional hallmarks of fibrocytes but mediate immune suppression. These cells are likely expanded in response to Th2 immune deviation and may contribute to tumor progression via both immune evasion and angiogenesis. •Myeloid cells in subjects with cancer contain fibrocytes, a cell subset previously implicated in chronic inflammation.•Fibrocytes in cancer patients are immunosuppressive and may contribute to immune escape.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0006-4971
1528-0020
1528-0020
DOI:10.1182/blood-2012-08-449413